PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2025 AND KEY EVENTS DURING THE PERIOD Financial and ...

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...

City of Hope® Research Spotlight offers a glimpse into groundbreaking scientific and clinical discoveries advancing lifesaving cures for patients with cancer, diabetes and other chronic, ...

A Worthing family are desperately trying to raise funds for private cancer treatment, after a devoted mother and grandmother was diagnosed with an aggressive form of leukaemia.

Ziftomenib showed significant efficacy in relapsed/refractory NPM1-mutant AML, achieving deep, durable responses in the KOMET-001 trial. The trial enrolled 92 patients, with 23% achieving complete ...

Antibody-drug conjugates (ADCs), often referred to as “intelligent biological missiles,” have garnered significant attention in the rapidly evolving landscape of cancer therapy. ADCs represent a ...

Panelists discuss how the greatest unmet needs include addressing poor outcomes in specific subsets like TP53-mutant disease, ...

Health care providers now recognize that determining treatment intensity requires careful evaluation of multiple patient factors beyond chronological age, including physiologic function, social ...

Brayden Cabral has been in remission for some time but he serves as inspirations for others who have gone or will go through a similar experience.

Results of a recently published long-term follow-up of the ASAP trial, which was conducted at universities and clinics across ...